Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.
Matsumiya M, Harris SA, Satti I, Stockdale L, Tanner R, O'Shea MK, Tameris M, Mahomed H, Hatherill M, Scriba TJ, Hanekom WA, McShane H, Fletcher HA. Matsumiya M, et al. Among authors: tameris m. BMC Infect Dis. 2014 Jun 9;14:314. doi: 10.1186/1471-2334-14-314. BMC Infect Dis. 2014. PMID: 24912498 Free PMC article. Clinical Trial.
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.
Tanner R, Kakalacheva K, Miller E, Pathan AA, Chalk R, Sander CR, Scriba T, Tameris M, Hawkridge T, Mahomed H, Hussey G, Hanekom W, Checkley A, McShane H, Fletcher HA. Tanner R, et al. Among authors: tameris m. BMC Infect Dis. 2014 Dec 3;14:660. doi: 10.1186/s12879-014-0660-7. BMC Infect Dis. 2014. PMID: 25466778 Free PMC article. Clinical Trial.
PET/CT guided tuberculosis treatment shortening: a randomized trial.
Malherbe ST, Chen RY, Yu X, Smith B, Liu X, Gao J, Diacon AH, Dawson R, Tameris M, Zhu H, Qu Y, Jin H, Pan S, Dodd LE, Wang J, Goldfeder LC, Cai Y, Arora K, Vincent J, Narunsky K, Serole K, Goliath RT, Da Costa L, Taliep A, Aziz S, Daroowala R, Thienemann F, Mukasa S, Court R, Sossen B, Ahlers P, Mendelsohn SC, White L, Gouel A, Lau CY, Hassan S, Liang L, Duan H, Moghaddam GK, Paripati P, Lahouar S, Harris M, Wollenberg K, Jeffrey B, Tartakovsky M, Rosenthal A, Duvenhage M, Armstrong DT, Song T, Winter J, Gao Q, Via LE, Wilkinson RJ, Walzl G, Barry CE. Malherbe ST, et al. Among authors: tameris m. medRxiv [Preprint]. 2024 Oct 4:2024.10.03.24314723. doi: 10.1101/2024.10.03.24314723. medRxiv. 2024. PMID: 39802795 Free PMC article. Preprint.
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.
Shinde V, Lombard Koen A, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche LF, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Joseph N, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen Jose A, Foulkes S, Ahmed K, Thombrayil A, Kalonji D, Cloney-Clark S, Zhu M, Bennett C, Albert G, Marcheschi A, Plested JS, Neal S, Chau G, Cho I, Fries L, Glenn GM, Madhi SA; 2019nCoV-501 Study Group. Shinde V, et al. Among authors: tameris m. Hum Vaccin Immunother. 2024 Dec 31;20(1):2425147. doi: 10.1080/21645515.2024.2425147. Epub 2024 Dec 12. Hum Vaccin Immunother. 2024. PMID: 39666396 Free article. Clinical Trial.
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.
Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM; AIDS Clinical Trial Group; Tuberculosis Trials Consortium. Chang VK, et al. Nat Commun. 2024 Oct 30;15(1):9400. doi: 10.1038/s41467-024-53273-7. Nat Commun. 2024. PMID: 39477924 Free PMC article. Clinical Trial.
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.
Bhiman JN, Richardson SI, Lambson BE, Kgagudi P, Mzindle N, Kaldine H, Crowther C, Gray G, Bekker LG; Novavax trial clinical lead author group; Shinde V, Bennett C, Glenn GM, Madhi SA, Moore PL. Bhiman JN, et al. Sci Rep. 2023 Jan 21;13(1):1222. doi: 10.1038/s41598-023-27698-x. Sci Rep. 2023. PMID: 36681693 Free PMC article.
T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection.
Musvosvi M, Huang H, Wang C, Xia Q, Rozot V, Krishnan A, Acs P, Cheruku A, Obermoser G, Leslie A, Behar SM, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Walzl G, Hatherill M, Davis MM, Scriba TJ; Adolescent Cohort Study team; GC6-74 Consortium. Musvosvi M, et al. Nat Med. 2023 Jan;29(1):258-269. doi: 10.1038/s41591-022-02110-9. Epub 2023 Jan 5. Nat Med. 2023. PMID: 36604540 Free PMC article.
99 results